Phase I clinical trials are designed to identify an appropriate dose for experimentation in phase II and III studies. I present the results from a simulation study to evaluate the performance of nine phase I designs involving the standard design, the two-stage modified Storer's design, the two-stage
Operating characteristics of the standard phase I clinical trial design
β Scribed by Ethan Reiner; Xavier Paoletti; John O'Quigley
- Publisher
- Elsevier Science
- Year
- 1999
- Tongue
- English
- Weight
- 208 KB
- Volume
- 30
- Category
- Article
- ISSN
- 0167-9473
No coin nor oath required. For personal study only.
β¦ Synopsis
In this communication we study the statistical properties of a widely used method for Phase I clinical trials. The designs typically applied in this context are derived from ΓΏxed sample versions of the Up and Down scheme deΓΏned by . Earlier investigations such as those by and concentrate mainly on the asymptotic and ΓΏxed sample properties of these procedures without dealing with the issue of early stopping. Our main focus is the standard scheme which includes a stopping rule as described by . Since it is felt that the advantage of the stopping rule is to use less subjects and to quickly proceed to phase II trials, we study the relationship between the total number of included patients and accuracy of the ΓΏnal recommendation. The error probabilities can all be worked out explicitly in any given situation and are studied over a large class of possible realities. We conclude that for trials that terminate after the inclusion of relatively few subjects the risk of choosing an incorrect level is large; much larger, we suspect, than is generally believed to be the case. Furthermore, it seems that any trial using such a stopping rule and concluding after having included less than 15 subjects is too unreliable to be of any use at all.
π SIMILAR VOLUMES
## Abstract ## BACKGROUND Patients in Phase I clinical trials sometimes report high expectations regarding the benefit of treatment. The authors examined a range of patient characteristics to determine which factors were associated with greater expectations of benefit from Phase I trials. ## METH
Phase I Clinical Trials in children with cancer are carried out with therapeutic intent, so as to define antileukemic/antitumor activity, dose-limiting toxicity, maximum tolerated dosage, and pharmacokinetics. These studies define a dosage of an agent or combination that may be used in a larger stud